Skip to main content
Category

News Archive

Holding place for old articles.

glycomimetics-logo

New Enterprise Associates owns 75 percent of GlycoMimetics – Washington Business Journal

By News Archive

glycomimetics-logo

Bicoastal venture firm New Enterprise Associates owns 75.2 percent of GlycoMimetics Inc., making NEA by far the biggest beneficiary of the Gaithersburg biotech’s planned initial public offering.

The company revealed NEA’s outsized ownership in its IPO paperwork, filed on Friday. It is not yet clear whether the firm, which has a major office in Chevy Chase, plans to sell some of its 26.7 million shares in the offering.

Read More
noble-life-sciences-logo

Neutropenic Mouse Thigh Model Now Offered by Noble Life Sciences

By News Archive

noble-life-sciences-logo

Noble Life Sciences (Gaithersburg, MD), in collaboration with ImQuest BioSciences (Frederick, MD), has successfully developed a neutropenic mouse thigh model of infection and demonstrated its use in a study evaluating vancomycin for the treatment of Staphylococcus aureus infection. The model will serve as a new Noble service for the evaluation of the efficacy of novel anti-microbial compounds in the treatment of microbial infections.

Complicated skin and soft tissue infections are frequently encountered in clinical practice and are a significant cause of morbidity and mortality in hospitalized patients. The neutropenic mouse thigh model of infection has been used extensively to test and benchmark antimicrobial drugs leading to a significant impact on our current knowledge of antimicrobial pharmacology. This model allows the quantitative comparison of different agents and different dosing regimes and the determination of the time-course of antimicrobial activity under conditions optimal for efficacy, i.e., neutropenia.

Read More
darpa-mil-gov-logo

Darpa Courts Biotech Researchers – Government – The Chronicle of Higher Education

By News Archive

darpa-mil-gov-logo

Donald E. Ingber, a professor at Harvard University, has combined advanced electronics and biology to create a “lung on a chip,” a breakthrough device that could safely allow precise tests of risky new medical treatments before they are tried out on humans.

Just as eye-opening as his work, however, may be his source of federal financing.

It’s not the National Institutes of Health, the $30-billion agency that is the largest provider of federal basic-research money to universities. Instead it’s the Defense Advanced Research Projects Agency, or Darpa, an agency one-tenth as large as NIH and responsible primarily for meeting the military’s technological needs.

Read More
king-rachel-glycomimetics

Glycomimetics Files Registration Statement for Proposed Initial Public Offering – GlycoMimetics

By News Archive

king-rachel-glycomimetics

glycomimetics-logo

GlycoMimetics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. GlycoMimetics has applied to list its common stock on the NASDAQ Global Market under the ticker symbol “GLYC.”

Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers for the proposed offering. Stifel is acting as co-lead manager and Canaccord Genuity Inc. is acting as co-manager.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by email at Prospectus_Department@Jefferies.com or by phone at 877-547-6340 or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at Barclaysprospectus@broadridge.com or by phone at 888-603-5847.

Read More

High Blood Sugar Linked with Cancer – TeleManagement

By News Archive

blood-cells-sxc

Even people without diabetes could be at higher risk of dying from disease

High blood sugar has been linked to a greater risk of dying from several types of cancer, a potentially worrying finding for countries with growing rates of obesity.

Researchers from Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, USA and Yonsei University in Seoul, Korea made the discovery by following more than 1.2 million Koreans for 10 years.

Read More
fyodor

Fyodor Awarded SBIR Phase 2 Grant

By News Archive

fyodor

Fyodor, a Baltimore-based biotechnology company, announced today that the US National Science Foundation (NSF) has awarded the company a Small Business Innovation Research (SBIR) Phase 2 grant. The $729,000 funding will help accelerate Fyodor’s effort to develop and validate a noninvasive multi-disease urine-based diagnostic test for Acute Febrile Illness (AFI), enabling the differential clinical diagnosis of leading global health diseases like malaria, typhoid, dengue, and leptospirosis from a single urine specimen in patients with fever.

Read More
NewImage

Epigenomics AG: Epigenomics signs joint commercialization agreement for Epi proColon® in North America with Polymedco

By News Archive

NewImage

Berlin, Germany, and U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, announced today that it has entered into a joint commercialization agreement with Polymedco Inc., a leading provider of colorectal cancer tests in North America. Both companies will jointly commercialize Epi proColon®, Epigenomics’ blood-based test for colorectal cancer (CRC) screening, in North America.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.